SCHEMBL19619965

C=C(C)[C@H](NC(=O)OC)C(=O)N1CC=C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CC(O)CN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1

nearest known ligand 0.55

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	CYP3A4	P08684	7/20	0.55

▸	CYP2C9	P11712	6/20	0.55

▸	KCNH2	Q12809	3/20	0.55

▸	NR1I2	O75469	2/20	0.55

▸	ABCB11	O95342	1/20	0.55

▸	OPRK1	P41145	1/20	0.55

▸	CYP1A2	P05177	3/20	0.51

▸	CYP2D6	P10635	2/20	0.50

▸	F11	P03951	3/20	0.33

▸	F2	P00734	1/20	0.33

▸	PRCP	P42785	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL19619963	0.94	CYP3A4 (0.62)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL16284222	0.94	CYP3A4 (0.62)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL19619842	0.88	CYP3A4 (0.54)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL19620079	0.87	CYP3A4 (0.56)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL19620135	0.86	CYP3A4 (0.52)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL19619844	0.86	CYP3A4 (0.52)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL19619839	0.86	CYP3A4 (0.54)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL19619958	0.86	CYP3A4 (0.52)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL12159632	0.86	CYP3A4 (0.72)	CYP3A4CYP2C9KCNH2NR1I2ABCB11
SCHEMBL19334233	0.86	CYP3A4 (0.72)	CYP3A4CYP2C9KCNH2NR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9820972-B2	Antiviral compounds highly effective as HCV-NS5A inhibitor	AB Pharma Ltd. (CN)	2017-11-21	—	—	US	disclosed